9 March 2020
Highlights from the Tumour Microenvironment and Immunology Meeting
Throughout the year, Oncode Institute organizes various workshops and trainings to share knowledge and facilitate collaboration. Together with Oncode Investigators Leila Akkari, Monika Wolkers and Jacques Neefjes, we recently organized the Tumour Microenvironment and Immunology Meeting in Veenendaal.
27 February 2020
A common gut microbe secretes a carcinogen
Cancer mutations can be caused by common gut bacteria carried by many people. This was demonstrated by researchers from the groups of Oncode Investigators Hans Clevers (Hubrecht Institute - KNAW) and Ruben van Boxtel (Princess Máxima Center).
27 February 2020
New colleagues at Oncode Institute
We are pleased to inform you about our new Oncode colleagues. Bianca-Olivia Nita started as a project communication manager, Jacqueline Staring is our new Program Manager and Evi Kallinikou joined as our new paralegal. We asked them to describe their role within Oncode briefly.
27 February 2020
Oncode Clinical Proof of Concept projects – status update
To support (pre)clinical projects, Oncode launched the Clinical Proof of Concept (CPoC) fund with an open call for proposals. One of the first projects that has received CPoC funding is ‘Head and neck cancer organoids and their potential to predict patient therapy response’ - a collaboration between the Hubrecht Institute, UMC Utrecht and Hubrecht Organoid Technology (HUB). We asked Else Driehuis - postdoc in Oncode Investigator Hans Clevers’ lab and Tech Transfer Scientist at HUB - about the progress and her experience with working on this project.
17 February 2020
Oncode Oncology Bridge Fund announces two Entrepreneurs in Residence
The Oncode Oncology Bridge Fund, launched by Oncode BV, is proud to announce the appointment of two Entrepreneurs in Residence (EIR’s). Dr. Markwin Velders (click for bio) brings over 25 years of research experience in the field of tumor immunology and over 18 years of management experience in biotechnology companies. Dr. Allard Kaptein (click for bio) is the Managing Director of Genase Therapeutics. Prior to that, he was co-founder of Acerta Pharma, spinning out the covalent BTK inhibitor series from MSD into Acerta Pharma.
17 February 2020
Oncode Institute appoints Chris De Jonghe as its new Valorization Director
Oncode Institute today announced that its Supervisory Board has appointed Chris De Jonghe as Valorization Director. Chris will start at Oncode Institute on May 4th and assumes her role as Valorization Director and all responsibilities on June 1st. Angus Livingstone, Oncode’s founding Valorization Director will stay with Oncode Institute until May 31st.
11 February 2020
Five Oncode Investigators win the first Ammodo Science Award for groundbreaking research
The winners of this award are the group behind the research project Guardians and Caretakers of the Genome based at the Erasmus MC and the research group Social Educational Neuroscience Amsterdam (SENSA) of the Vrije Universiteit Amsterdam. They each receive a cash prize of 1.2 million euros which they will use to explore new areas of research. Oncode Investigators Jurgen Marteijn, Wim Vermeulen, Roland Kanaar, Jan Hoeijmakers and Miao-Ping Chien are part of the Erasmus MC research project.
3 February 2020
World cancer day: the importance of patient engagement within cancer research
- Open article for English - 4 februari is het wereldkankerdag. Erica van Wuijtswinkel, patiëntvertegenwoordiger bij de Raad van Toezicht van Oncode Institute, legt uit waarom patiëntenparticipatie zo belangrijk is binnen kankeronderzoek. Ze bespreekt ook hoe zij haar rol binnen Oncode Institute invult en hoe Oncode patiëntenparticipatie heeft ingebed in de organisatie.
26 January 2020
Oncode researchers gain access to Organoid technology thanks to collaboration with KNAW
Thanks to an agreement between the Royal Netherlands Academy of Arts and Sciences (KNAW) and Oncode Institute, the organoid technology will become available to all 800+ cancer researchers that are part of Oncode. The KNAW collaborates with its institutional partner UMC Utrecht on organoid technology. Thanks to this agreement with Oncode, researchers receive a license to conduct research on organoids for the first time in the Netherlands.
23 January 2020
Venom-producing snake organoids developed in the lab
Researchers from the group of Oncode Investigator Hans Clevers, together with Oncode Investigators Anne Rios, Alexander van Oudenaarden and many others, have developed a method to grow snake venom gland cells as organoids. These lab-grown mini glands produce and secrete active toxins found in snake venom. Snake venom gland organoids can be grown from multiple species and maintained in the lab indefinitely. This new technology holds great promise to reduce the devastating impact and exploit the secrets of snake venom. The results of this research were published in the scientific journal Cell on the 23rd of January.
Scroll for more